Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy.
Cytotoxic T lymphocytes (CTL) and highly active antiretroviral therapy (HAART) are known to exert strong evolutionary pressures on the virus population during human immunodeficiency virus (HIV) infection. However, it is not known whether CTL responses continue to substantially affect viral evolution during treatment. To study the effect of immunologic pressure on viral sequences during HAART, we identified 10 targeted HIV-specific CD8+-T-cell epitopes in five treatment-naive patients, sequenced each epitope in plasma-derived viruses, and then identified evidence of immunologic pressure at these epitopes by comparing the frequency of viral variants in plasma to the frequency of the CD8+-T-cell response for each variant identified. For one of the five patients, evidence of viral evolution was found during therapy. The sequence of the CTL-targeted epitope changed from an apparent escape variant prior to the initiation of therapy, to the sequence that is best recognized by the CTL response after the initiation of therapy, and then finally to a new escape variant during continued therapy. These data show that CTL-mediated pressure can continue to affect viral evolution after the initiation of HAART, even when treatment drives the viral load below detectable levels, and suggest that antiretroviral therapy may preferentially inhibit those virus variants that escape the CTL response.
Casazza
Joseph P
JP
Immunology Laboratory, National Institutes of Health, Bethesda, MD 20892, USA.
Betts
Michael R
MR
Hill
Brenna J
BJ
Brenchley
Jason M
JM
Price
David A
DA
Douek
Daniel C
DC
Koup
Richard A
RA
D019943:Amino Acid Substitution; D023241:Antiretroviral Therapy, Highly Active; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000276:immunology; D019143:Evolution, Molecular; D006678:HIV / Q000187:drug effects / Q000235:genetics* / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D020125:Mutation, Missense; D012641:Selection, Genetic; D017422:Sequence Analysis, DNA; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D018984:Epitopes, T-Lymphocyte; D015488:HIV Antigens; D006680:HLA Antigens
J Gen Virol. 1997 Jul;78 ( Pt 7):1511-9
9225023
N Engl J Med. 1999 May 27;340(21):1614-22
10341273
J Exp Med. 1996 Apr 1;183(4):1917-21
8666949
J Exp Med. 1999 Mar 15;189(6):991-8
10075982
J Exp Med. 2001 Feb 5;193(3):375-86
11157057
J Virol. 2002 Sep;76(17):8690-701
12163589
J Virol. 2003 Jul;77(13):7330-40
12805431
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
12520007
J Virol. 2001 Jul;75(14):6508-16
11413318
Nature. 2000 Sep 28;407(6803):523-6
11029005
Nat Med. 1999 Nov;5(11):1270-6
10545993
Curr Protoc Immunol. 2003 Nov;Chapter 18:Unit 18.11
18432904
J Virol. 2002 Sep;76(18):9481-92
12186930
Nature. 1998 Dec 17;396(6712):690-5
9872319
J Clin Invest. 1999 Sep;104(6):R13-8
10491418
J Virol. 1999 Jan;73(1):797-800
9847391
J Virol. 1994 Sep;68(9):6103-10
8057491
N Engl J Med. 1981 Dec 10;305(24):1431-8
6975437
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1890-5
9050875
JAMA. 2001 Jul 11;286(2):171-9
11448280
J Clin Invest. 2002 Nov;110(9):1339-47
12417573
Virology. 2002 Oct 25;302(2):393-404
12441083
Immunogenetics. 1985;21(3):235-46
3872841
J Virol. 1999 Nov;73(11):9404-12
10516049
Nat Med. 2000 Jan;6(1):82-5
10613829
N Engl J Med. 1981 Dec 10;305(24):1425-31
6272109
Tissue Antigens. 1995 Feb;45(2):81-90
7792765
J Virol. 2002 Oct;76(20):10169-76
12239291
Nat Med. 1995 Apr;1(4):330-6
7585062
Science. 1999 Feb 5;283(5403):857-60
9933172
J Clin Invest. 1997 Feb 15;99(4):752-62
9045880
J Immunol. 2003 Jul 1;171(1):477-88
12817033
N Engl J Med. 1999 May 27;340(21):1605-13
10341272
Top HIV Med. 2003 Nov-Dec;11(6):215-21
14724329
Nature. 1994 Aug 11;370(6489):463-7
8047166
JAMA. 2001 Jul 11;286(2):196-207
11448283
Nature. 1997 May 8;387(6629):188-91
9144290
Science. 1996 Mar 15;271(5255):1582-6
8599114
Nat Med. 1998 Aug;4(8):975-8
9701254
Annu Rev Immunol. 1997;15:271-96
9143689
J Virol. 2002 Nov;76(21):10674-84
12368309
Nat Med. 1997 Feb;3(2):212-7
9018241
AIDS. 1999 Sep 10;13(13):1687-95
10509570
Science. 2000 Oct 20;290(5491):486-92
11039923
J Virol. 2004 Jul;78(13):7069-78
15194783
J Virol. 2000 Nov;74(22):10269-73
11044070
J Virol. 1994 Jul;68(7):4650-5
8207839
J Virol. 1996 Aug;70(8):5720-30
8764096
Nat Med. 1997 Feb;3(2):205-11
9018240
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254-8
8990195
Science. 2002 May 24;296(5572):1439-43
12029127